Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy

Urology
Joseph HermanHoward M Sandler

Abstract

To assess, in a Phase I study, whether bladder preservation with concurrent gemcitabine and radiotherapy (RT) influenced patient-reported quality of life (QOL) as determined by the Functional Assessment of Cancer Therapy-Bladder (FACT-BL). Between January 1998 and March 2002, 24 patients with urothelial carcinoma of the bladder were enrolled, and 23 patients underwent transuretheral resection of bladder tumor, followed by twice-weekly gemcitabine with concurrent RT. The initial dose was 10 mg/m2 given twice weekly and increased as tolerated. To assess treatment-related QOL, patients completed the FACT-BL questionnaire. Of the 24 patients enrolled, 23 (96%) were assessed for toxicity and response. The FACT-generic (G) QOL assessment was obtained from 22 (92%) of 23 patients. No statistically significant difference was found in the FACT-G or FACT-BL or the combination before, during, or after treatment. The FACT-BL values were lower in patients who received higher doses of gemcitabine (greater than 20 mg/m2 versus 20 mg/m2 or less). At least one dose-limiting toxicity (DLT) was experienced by 5 (23%) of 22 patients. The FACT-G values were lower for those patients who experienced DLT (difference of -13.1, P = 0.07). The physical w...Continue Reading

References

Jun 1, 1999·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·N MiyanagaJ Hinotsu
Jul 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claus RödelRolf Sauer
Dec 31, 2002·Expert Review of Anticancer Therapy·Syed A Hussain, Nicholas D James
Apr 4, 2003·Cancer·William U ShipleyUNKNOWN Radiation Therapy Oncology Group
Jun 20, 2003·European Urology·M KuczykUNKNOWN European Society for Oncological Urology

❮ Previous
Next ❯

Citations

Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason A EfstathiouHoward M Sandler
Sep 10, 2011·Therapeutic Advances in Urology·Arjun BalarMatthew I Milowsky
Sep 23, 2009·Current Treatment Options in Oncology·David J Gallagher, Matthew I Milowsky
Oct 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Linda E Carlson, Sheila Garland
Dec 4, 2009·Expert Review of Anticancer Therapy·Faysal A YafiWassim Kassouf
Oct 24, 2012·Critical Reviews in Oncology/hematology·Orazio CaffoEnzo Galligioni
Apr 14, 2010·International Journal of Radiation Oncology, Biology, Physics·Jean-Léon LagrangeUNKNOWN Study Group on Genito-Urinary Tumors
Nov 4, 2008·International Journal of Radiation Oncology, Biology, Physics·Kevin S OhHoward M Sandler
Mar 27, 2007·Seminars in Oncology·Shaneli A Fernando, Howard M Sandler
May 2, 2006·Cancer·Veerasathpurush AllareddyBadrinath R Konety
Jan 26, 2005·International Journal of Radiation Oncology, Biology, Physics·Vijay K SangarRichard A Cowan
Sep 8, 2015·Current Urology Reports·Michael A Feuerstein, Anuj Goenka
Oct 11, 2016·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Orazio CaffoAnanya Choudhury
Sep 9, 2020·Japanese Journal of Clinical Oncology·Tomokazu KimuraHiroyuki Nishiyama
Dec 21, 2004·Expert Review of Anticancer Therapy·Umberto BassoSilvio Monfardini
Mar 3, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Arnold DegboeDavid Cella
Nov 25, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Teruo InamotoHaruhito Azuma
Dec 3, 2020·Minerva urologica e nefrologica = The Italian journal of urology and nephrology·Elvira Polo-AlonsoMaria C Mir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.